Bethania Pérez Alves,* Mateo Balado Rico, Francisco Javier Esteban Fernández, Javier Sánchez Ayuso

Servicio de Medicina Interna, Hospital Universitario de Getafe, Getafe, Madrid, Spain * Corresponding author. *E-mail address:* betha.peralves@gmail.com (B. Pérez Alves).

1579-2129/ © 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Sarcoidosis-Like Granulomatous Reaction Associated with Pembrolizumab Immunotherapy^{*}

Reacción granulomatosa sarcoidosis-like asociada al tratamiento con inmunoterapia (pembrolizumab)

Dear Editor,

The recent introduction of immunotherapy in the treatment of cancer has revolutionized the management of some tumors, including lung cancer,¹ and this treatment is being progressively included in the various therapeutic guidelines. Pembrolizumab is a humanized anti-PD1 monoclonal antibody that is approved in Spain for the treatment of non-small cell lung cancer, in both first and second-line treatment in selected patients,² and in metastatic melanoma. We report the case of a patient with a diagnosis of metastatic melanoma treated with pembrolizumab, who developed a granulomatous sarcoidosis-like reaction to this treatment, a little-known adverse effect that is rarely described in the literature.

This was a 72-year-old man, former smoker of 50 pack-years, with no respiratory history, diagnosed with a superficial melanoma after excision of a mole from the lower left limb in 2014, with subsequent widening of surgical borders. After 2 disease-free years, metastases were detected in the left inguinal lymph nodes, and lymphadenectomy was performed. Unresectable mesenteric lymphadenopathies subsequently appeared, so treatment began with pembrolizumab every 3 weeks.

After 6 months of treatment, with partial response of the lymphadenopathies, the respiratory medicine department was consulted due to the appearance on a follow-up chest CT of septal thickening, nodules predominantly in the subpleural and fissure regions, and hilar and mediastinal lymphadenopathies measuring up to 15 mm, changes highly suggestive of a sarcoidosis-like granulomatous reaction (Fig. 1). Chest CT before starting treatment showed no changes in the pulmonary parenchyma and no mediastinal lymphadenopathies.

The patient was asymptomatic at all times, with no respiratory symptoms, cough, dyspnea or fever, nor did he present new skin lesions. The examination revealed bibasal crackles and edema of the lower limbs (secondary to lymphadenectomy), and basal pulse oximetry was 95%. Angiotensin-converting enzyme was 54 U/l and functional respiratory tests were normal. Fiberoptic bronchoscopy was performed, and no endobronchial changes were visualized. Bronchoalveolar lavage was consistent with lymphocytic alveolitis, with a CD4/CD8 ratio of 1.1. Five transbronchial biopsies were obtained that showed non-caseifying epithelioid granulomas (Fig. 1). All microbiological analyses of lavage and biopsy material were negative, including mycobacteria testing.

Check fo

Given the consistent radiological and histological findings and the correlation in time with the treatment, the patient was diagnosed with sarcoidosis-like granulomatous reaction associated with pembrolizumab. As he was asymptomatic and lung function was normal, we decided, in consultation with the oncology department, to discontinue pembrolizumab and to monitor the patient. In the chest CT performed 1 month after withdrawing treatment, partial radiological improvement was seen, both in parenchymal involvement and in the size of the lymphadenopathies, so this approach was maintained. Six months after discontinuing the drug, the follow-up CT showed that the radiological changes had resolved almost completely. The good response to merely discontinuing pembrolizumab confirmed that the sarcoid reaction was directly related to the treatment.

Immunotherapy is defined as the set of treatments aimed at strengthening the immune system to promote the development of antitumor activity. These drugs act by unblocking key inhibitory lymphocyte pathways, such as the CTLA-4 or PD-1/PDL-1 pathway, resulting in the stimulation of T cell activity.³ This activation helps the immune system to attack tumor cells, although it can also increase the chance of host tissue reactions. For this reason, adverse effects associated with these treatments are often autoimmune events, the most common being skin rashes, colitis, liver disease, pneumonitis, and endocrine diseases. The respiratory adverse effects reported in clinical trials include cough, dyspnea, bronchitis, organizing pneumonia, hoarseness, pulmonary fibrosis, and particularly, pneumonitis, which is potentially the most serious.^{4,5} A meta-analysis of 653 patients treated with pembrolizumab estimated a rate of pneumonitis of 6%, and described 5 typical radiological patterns: cryptogenic organizing pneumonia, ground glass pattern, hypersensitivity type, interstitial, and nonspecific.⁶

Sarcoidosis-like granulomatous reactions have already been described in association with other cancer treatments, such as alpha-interferon or cisplatin,⁷ or monoclonal antibodies, such as anti-tumor necrosis factor or anti-CD20. These reactions have also been described recently in some cases in association with immunotherapy. In 2008, the first case of sarcoidosis-like granulomatous reaction associated with ipilimumab (anti-CTLA-4) was reported in a patient with metastatic melanoma.⁸ Another 13 cases with this drug were subsequently published, 12 in the treatment of melanoma and 1 in prostatic adenocarcinoma. Three cases associated with nivolumab (anti-PD1), also in melanoma, have been published, the first in 2016.⁹ With regard to treatment with pembrolizumab, only 5 confirmed cases have been described, 4 in melanoma^{10–12} and 1 in metastatic leiomyosarcoma.¹³ Another 3 cases of reactivation of granulomatous disease prior to initiating immunotherapy (2 treated with pembrolizumab¹⁴ and 1 with a combination of ipilimumab and nivolumab) have been published.

These reactions are treated by discontinuing the drug and administering corticosteroids, depending on the degree of involvement. According to guidelines for managing immune-mediated adverse effects,^{5,15} asymptomatic cases can be managed simply with close monitoring, while corticosteroids should be reserved

^{*} Please cite this article as: Gayá García-Manso I, García Ródenas MdM, Barroso Medel ME, Illán Gambín FJ. Reacción granulomatosa sarcoidosis-like asociada al tratamiento con inmunoterapia (pembrolizumab). Arch Bronconeumol. 2018;54:592–593.



Fig. 1. Left: chest HRCT slices showing septal thickening, with nodules predominantly in the subpleural and fissure regions. Mediastinum showing presence of hilar and mediastinal lymphadenopathies measuring up to 15 mm. Right: transbronchial biopsy specimen showing non-caseifying epithelioid granulomas. Multinucleated giant cells grouping to form granulomas with scant accompanying lymphocytic cellularity. No necrosis identified.

for the appearance of symptoms or progression, while immunosuppressants can be added in severe cases. In all published cases, sarcoid involvement concluded with resolution of the lesions, irrespective of the use of corticosteroids or drug suspension. The adverse effects of our patient, for example, resolved almost completely merely by discontinuing pembrolizumab.

In conclusion, it is important to remain alert to the possibility of this adverse effect: very few cases have been described to date, but the increase in the use of immunotherapy and the widespread use of these drugs in more and more types of cancer may prompt a significant increase in the incidence of these reactions in coming years. Moreover, we should be careful about assuming that the appearance of mediastinal lymphadenopathies in patients receiving these drugs is due to tumor progression, since it may be a granulomatous reaction, and the diagnosis must be confirmed by biopsy.

References

- Sánchez de Cos J. Nueva inmunoterapia y cáncer de pulmón. Arch Bronconeumol. 2017;53:682–7.
- Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.
- **3.** Pennock GK, Chow LQM. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20:1–11.
- Naidoo J, Page DB, Li BT, Connell LE, Schindler K, Lacouture ME, et al. Toxicities and anti-PD1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375–91.
- O'Kane GM, Labré C, Doherty MK, Young K, Albalá H, Leigbl NB, et al. Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer. Oncologist. 2017;22:70–80.
- Naidoo J, Cunningham J, Woo KM, Hellman MD, Postow MA, Drilon AE, et al. Pneumonitis with anti-PD-1/PD-L1 therapy. Eur J Cancer. 2015;51:S103.
- 7. Cohen PR, Kurzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007;25:326–33.

- Eckert A, Schoeffler A, Dalle S, Phan A, Kiakouama L, Thomas L. Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology. 2009;218:69–70.
- Danlos FX, Pages C, Baroudjian B, Vercellino L, Battistella M, Mimoun M, et al. Nivolumab-induced sarcoid-like granulomatous reaction in a patient with advanced melanoma. Chest. 2016;149:e133–6.
- Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017;23:620–4.
- **11.** Burillo-Martinez S, Morales-Raya C, Prieto-Barrios M, Rodriguez-Peralto JL, Ortiz-Romero PL. Pembrolizumab-induced extensive panniculitis and nevus regression: 2 novel cutaneous manifestations of the post-immunotherapy granulomatous reactions spectrum. JAMA Dermatol. 2017;153:721–2.
- Tetzlaff MT, Nelson KC, Diab A, Staerkel GA, Nagarajan P, Torres-Cabala CA, et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018;6:14.
- **13.** Cousin S, Toulmonde M, Kind M, Cazeau AL, Bechade D, Coindre JM, et al. Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab. Ann Oncol. 2016;27:1178–9.
- Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Pembrolizumabassociated sarcoidosis. JAAD Case Rep. 2016;2:290–3.
- Weber JS, Postow M, Lao CD, Schadendorf D. Management of adverse events following treatment with anti-programmed death-1 agents. Oncologist. 2016;21:1230–40.

Ignacio Gayá García-Manso,^{a,*} María del Mar García Ródenas,^a María Encarnación Barroso Medel,^a Francisco José Illán Gambín^b

^a Neumología, Hospital General Universitario de Alicante, Alicante, Spain

^b Anatomía Patológica, Hospital General Universitario de Alicante, Alicante, Spain

* Corresponding author.

E-mail address: nachogaya@gmail.com (I. Gayá García-Manso).

1579-2129/

© 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.